| Dr Elliot K Mathias, MD | |
|
110 Commerce Dr, Shelton, CT 06484-6244 | |
| (203) 929-7331 | |
| (203) 925-0330 |
| Full Name | Dr Elliot K Mathias |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 49 Years |
| Location | 110 Commerce Dr, Shelton, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1871669978 | NPI | - | NPPES |
| 1205582 | Medicaid | CT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 20558 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Griffin Hospital | Derby, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Griffin Faculty Physicians Inc | 7618871997 | 107 |
News Archive
Gilead Sciences, Inc. today announced that its head-to-head Phase III clinical trial of Cayston (aztreonam for inhalation solution) versus tobramycin inhalation solution in cystic fibrosis patients with Pseudomonas aeruginosa achieved one of its co-primary endpoints of non-inferiority for mean percent change in forced expiratory volume in one second (FEV1) percent predicted after 28 days of treatment.
"In a letter to leaders of Congress, the secretary of health and human services, Kathleen Sebelius, reported on Monday that the Obama administration is moving quickly to carry out the expansive new health care law, particularly provisions that she referred to as 'early insurance market reforms,'" The New York Times reports.
Results from a landmark study involving more than 9,000 people showed that the high blood pressure medicine valsartan delayed progression to type 2 diabetes in patients with cardiovascular disease or risk factors and impaired glucose tolerance (IGT), a common pre-diabetic condition.
Scientists at the University of California, Berkeley, have developed a novel way to engineer the growth and expansion of energy-burning "good" fat, and then found that this fat helped reduce weight gain and lower blood glucose levels in mice.
› Verified 3 days ago
| Entity Name | Griffin Faculty Physicians Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598755605 PECOS PAC ID: 7618871997 Enrollment ID: O20031120000158 |
News Archive
Gilead Sciences, Inc. today announced that its head-to-head Phase III clinical trial of Cayston (aztreonam for inhalation solution) versus tobramycin inhalation solution in cystic fibrosis patients with Pseudomonas aeruginosa achieved one of its co-primary endpoints of non-inferiority for mean percent change in forced expiratory volume in one second (FEV1) percent predicted after 28 days of treatment.
"In a letter to leaders of Congress, the secretary of health and human services, Kathleen Sebelius, reported on Monday that the Obama administration is moving quickly to carry out the expansive new health care law, particularly provisions that she referred to as 'early insurance market reforms,'" The New York Times reports.
Results from a landmark study involving more than 9,000 people showed that the high blood pressure medicine valsartan delayed progression to type 2 diabetes in patients with cardiovascular disease or risk factors and impaired glucose tolerance (IGT), a common pre-diabetic condition.
Scientists at the University of California, Berkeley, have developed a novel way to engineer the growth and expansion of energy-burning "good" fat, and then found that this fat helped reduce weight gain and lower blood glucose levels in mice.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Elliot K Mathias, MD 67 Maple Ave, Derby, CT 06418-1328 Ph: (203) 732-1330 | Dr Elliot K Mathias, MD 110 Commerce Dr, Shelton, CT 06484-6244 Ph: (203) 929-7331 |
News Archive
Gilead Sciences, Inc. today announced that its head-to-head Phase III clinical trial of Cayston (aztreonam for inhalation solution) versus tobramycin inhalation solution in cystic fibrosis patients with Pseudomonas aeruginosa achieved one of its co-primary endpoints of non-inferiority for mean percent change in forced expiratory volume in one second (FEV1) percent predicted after 28 days of treatment.
"In a letter to leaders of Congress, the secretary of health and human services, Kathleen Sebelius, reported on Monday that the Obama administration is moving quickly to carry out the expansive new health care law, particularly provisions that she referred to as 'early insurance market reforms,'" The New York Times reports.
Results from a landmark study involving more than 9,000 people showed that the high blood pressure medicine valsartan delayed progression to type 2 diabetes in patients with cardiovascular disease or risk factors and impaired glucose tolerance (IGT), a common pre-diabetic condition.
Scientists at the University of California, Berkeley, have developed a novel way to engineer the growth and expansion of energy-burning "good" fat, and then found that this fat helped reduce weight gain and lower blood glucose levels in mice.
› Verified 3 days ago
Mrs. Brittany Herman, APRN Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 887 Bridgeport Ave, Shelton, CT 06484 Phone: 203-225-6020 | |
Dr. Saroja Koneswaran, MD Family Medicine Medicare: May Accept Medicare Assignments Practice Location: 21 Huntington Plaza, Shelton, CT 06484 Phone: 203-929-6358 Fax: 203-929-3826 | |
Dr. Elizabeth Arbia, D.O. Family Medicine Medicare: Medicare Enrolled Practice Location: 110 Commerce Dr, Shelton, CT 06484 Phone: 203-929-7331 Fax: 203-925-0330 | |
Stephanie J Rowe, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 887 Bridgeport Ave, Shelton, CT 06484 Phone: 203-225-6020 Fax: 203-384-3829 | |
Dr. Kenneth Ward, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 110 Commerce Dr, Shelton, CT 06484 Phone: 203-929-7331 Fax: 203-925-0330 | |
Dr. Fadeke O Longe, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 4 Corporate Dr, Shelton, CT 06484 Phone: 203-225-0375 | |
Dr. Bharvi Ashok Balar, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 224 Leavenworth Rd, Shelton, CT 06484 Phone: 203-926-1206 Fax: 203-926-0413 |